1247-42-3

Usage

Uses

Used in Pharmaceutical Industry:
Meprednisone is used as a corticosteroid for its anti-inflammatory and immunosuppressive effects. It is prescribed for a wide range of conditions, including rheumatoid arthritis, lupus, asthma, and various skin disorders. Its ability to reduce inflammation and suppress the immune system makes it an effective treatment for these conditions.
Used in Betapar (Schering):
Meprednisone is used as the active ingredient in the brand Betapar, which is manufactured by Schering. This brand is specifically formulated to provide the therapeutic benefits of Meprednisone to patients in need of corticosteroid treatment.

Originator

Betapar,Parke Davis,US,1970

Manufacturing Process

16β-Methylprednisone 21-acetate (0.5 g), when hydrolyzed by means of aqueous alcoholic potassium bicarbonate yields 16β-ethylprednisone. An alternative method of the preparation of the compound of this example is as follows. Bacillus sphaericus var. fusifermis (A.T.C.C. 7055) is incubated on a nutrient agar (composed of Bacto-beef extract, 3 g; Bacto-peptone, 5 9; sodium chloride, 8 9; agar, 15 g; and tap water, 1 liter) for 24 hours at 28°C. To 100 ml of a sterile nutrient broth (composed of Bacto-beef extract, 3 9; Bacto-peptone, 5 9; per liter of tap water) in a 300 ml flask is added one loopful of the incubated culture and the broth mixture is further incubated for 24 hours at 28°C on a shaking machine. The broth culture so obtained is employed as an inoculum (1%). Into each of ten flasks containing 100 ml of sterile nutrient broth is added 1 ml of the inoculum. The flasks are agitated on a rotary shaker for 8 hours at 28°C at 240 strokes per minute. After this growth period, a solution of 25 mg of 16β-methylcortisonein 0.5 ml of methanol is aseptically added to each flask which in turn is reshaken and incubated for an additional 24 hours. The final pH is 7.8. The contents of the flasks are then combined and extracted 3 times with two liters of chloroform per extraction. The combined chloroform extracts are evaporated to dryness yielding 310 mg of crude product. The crude steroid is purified by chromatography on a chromatographic system described by G.M. Shull, Abstracts of Papers of the 126th Meeting of the American Chemical Society, December 12-17, 1954, page 9a, paper No. 24. Chromatographic evaluation shows a quantitative conversion of the starting material to the diene when an authentic sample of the 16β-methylprednisone is used as a control. Alternatively, the crude product is recrystallized from acetone affording 225 mg of 16β-methylprednisone.

Therapeutic Function

Glucocorticoid

InChI:InChI=1/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16?,19?,20-,21-,22-/m0/s1

Upstream product

• 1106-03-2 21-acetoxy-17-hydroxy-16β-methyl-pregna-1,4-diene-3,11,20-trione 
• 1253-36-7 21-acetoxy-17-hydroxy-16β-methyl-5β-pregnane-3,11,20-trione 
• 75-16-1 methylmagnesium bromide 

Related news

Comparative analysis the binding affinity of mycophenolic sodium and Meprednisone (cas 1247-42-3) with human serum albumin: Insight by NMR relaxation data and docking simulation08/04/2019

Mycophenolic sodium is an immunosuppressive agent that is always combined administration with corticosteroid in clinical practice. Considering the distribution and side-effect of the drug may change when co-administrated drug exist, this paper comparatively analyzed the binding ability of mycoph...detailed

Relevant academic research and scientific papers

Preparation method of methyl metacortandracin

The invention discloses a preparation method of methyl metacortandracin. The methyl metacortandracin is prepared by taking 16-b methyl-9 (11) a-epoxy-prednisolone acetate (called as DB11 for short) as a raw material; dissolving the raw material in an organic solvent and reacting with hydrobromic acid to obtain bromine hydroxyl content 9a bromine-16b methyl-prednisolone acetate; performing catalytic hydrogenation and 9-bit debromination on bromine hydroxyl content in the organic solvent by acid-binding agent and palladium carbon to obtain a debromination matter 16b methyl-metacortandracin; oxidizing the debromination matter with strong oxidant in the organic solvent to obtain prednisolone acetate; finally, hydrolyzing the prednisolone acetate in the organic solvent by catalyst to obtain methyl metacortandracin. The total weight yield through four-step synthesis is 52-55%. The production method is wide in raw material source, economic and environment-friendly in technique, short in synthesis route, and high in production yield; the production cost is 30-40% lower than that of the traditional method, and 15-20% lower than the method of application number 201610952306.6; the technique is simple and convenient; the solvent can be recycled and used indiscriminately; the preparation method is easy to practice the industrial production.

Methylprednisilone preparation method (by machine translation)

Methylprednisilone preparation method, is made up of 4 - androstenedione (abbreviated as 4AD) preparation of the 16 (17) a - epoxy prednison in organic solvent with the glycol in 10 - 50 °C shall ketal acid catalyzed reaction: 20 - shrinks the keto - 16a (17) - epoxy prednison; then the ketal in organic solvent with the three a chlorosilane silicon ether alkali catalytic reaction shall be: 21 - a silicon ether base - 20 - shrinks the keto - 16a (17) - epoxy prednison; then the silicon ether in organic solvent with the 2M methyl magnesium halide Grignard reaction, in the strong acid in the resulting standard hydrolyze methylprednisilone, HPLC content detected 99.0% or more, melting point 228 - 237 °C, synthetic weight total yield of 80 - 85%. To the invention producing methyl prednisone, raw material sources are extensive, process economic and environmental protection, simple and convenient production operation, short synthetic route, synthetic high yield, low production cost compared to the conventional method of 30 - 40%; is favorable for industrial production. (by machine translation)

Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.